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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S72Purpose: Hand osteoarthritis (OA) is one of the most common locali-
zation of OA, affecting predominantly women. Patients with knee, hip
or spine OA exhibit increased cartilage type II collagen degradation as
detected by the urinary excretion of C-terminal crosslinking telopeptide
of type II collagen (CTX-II), but data on hand OA are lacking. The aim of
this study was to investigate the relationship between urinary CTX-II
and hand OA in women.
Subjects and Methods: We investigated 590 women from the OFELY
population-based study (mean age: 61.8 years  10.2) including 475
postmenopausal women. Clinical hand OAwas deﬁned according to the
ACR criteria (Altman et al, 1990) slightly modiﬁed (without functional
complains). At the same time of hand OA evaluation, knee and spine OA
were assessed by radiographs and self-reported hip OA was recorded.
Levels of urinary CTX-II measured by ELISA (Urine CartiLaps, IDS) in
the 186 women with hand OA (mean age: 67.2 years  8.4) were
compared to those of the 404 other women without hand OA (mean
age: 59.4 years  10.1). All analyses were adjusted for age and
concomitant knee, hip or spine OA.
Results: Urinary CTX-II levels were signiﬁcantly increased in women
with hand OA (+ 45% vs controls, p¼ 0.001) after adjustment for age and
for knee, spine and hip OA). When urinary CTX-II concentrations were
considered in quartiles, subjects with levels in the highest quartile had
an increased risk of presenting with hand OA, with an odds-ratio of 2.06
(95% CI: 1.3-3.2; p ¼ 0.002) after adjustment for OA at the other
anatomical sites.
Conclusion: Hand OA is characterized by increased type II collagen
degradation. Urinary CTX-II could be a useful biomarker for the clinical
investigation of hand OA.118
TNF-a IS ELEVATED IN SYNOVIAL FLUID OF PATIENTS WITH AN
ANTERIOR CRUCIATE LIGAMENT RUPTURE 5 YEARS AFTER THE
INJURY. PRO-INFLAMMATORY CYTOKINES IN SYNOVIAL FLUID AND
SERUM – A PROSPECTIVE LONGITUDINAL STUDY
M. Hansson y, S. Larsson y, R. Frobell y, L.S. Lohmander y,z,
A. Struglics y. y Lund Univ., Clinical Sci. Lund, Lund, Sweden; zRes. Unit for
Musculoskeletal Function and Physiotherapy, and Dept.s of Orthopaedics
and Traumatology, Univ. of Southern Denmark, Odense, Denmark
Purpose: Trauma induced cytokine response in knee injuries may play
a role in the development of osteoarthritis (OA) since knee injuries areTable 1
Cytokine concentrations (pg/ml) in SF and serum expressed as medians (25th–75th percen
at different time. Half LLOQ values: IL-10, 1.0; IL-6, 0.3; IFN-g, 0.6.
Groups n IL-8
Conc. P-values
Ref 20 13.8 (9.6-83.2) -
23 9.0 (5.8-14.9) -
Baseline 51 89.2 (47.8-189.7) <0.001
119 5.8 (4.5-7.6) <0.001
16 weeks 50 29.4 (16.2-77.1) 0.091
64 6.1 (4.4-10.9) 0.067
30 weeks 47 23.4 (16.2-37.9) 0.279
63 6.5 (4.8-9.2) 0.041
52 weeks 47 20.1 (10.9-37.1) 0.722
63 6.3 (4.6-8.9) 0.018
104 weeks 81 15.8 (11.6-26.2) 0.878
118 5.5 (4.4-7.4) <0.001
260 weeks 64 10.6 (7.4-14.4) 0.046
114 5.8 (4.6-7.5) 0.002
Groups n IL-6
Conc.
Ref 20 0.7 (0.3-8.2)
Baseline 51 1271.1 (321.0-3614.7)
16 weeks 50 11.2 (3.3-33.1)
30 weeks 47 3.2 (0.6-16.5)
52 weeks 47 1.3 (0.3-5.7)
104 weeks 81 1.0 (0.3-4.0)
260 weeks 64 0.7 (0.3-2.5)often a gateway to OA. Cytokines regulate responses to infection,
inﬂammation and trauma, attract leucocytes to the affected tissue, and
are involved in tissue destructionmediated bymatrix metalloproteases.
Blocking of cytokines (e.g. TNF-a) has been successful in the treatment
of patients with rheumatoid arthritis. As part of a longitudinal study
(KANON study), wherewe aim to analyze different outcomes in patients
suffering from ruptured anterior cruciate ligaments (ACL), we here
report the pro-inﬂammatory cytokine levels in synovial ﬂuid (SF) and
serum at different times after injury.
Methods: SF and serum was collected from ACL injured patients
(n¼121) 0-3 weeks (baseline), at 16, 30, 52, 104 and 260 weeks after the
injury. Mean age of the included patients was 26 years (range 18-35)
and 74% were male. Samples from knee healthy subjects (reference
group n¼23) matched for age were included. Pro-inﬂammatory cyto-
kines (IL-1b, IL-6, IL-8, IL-10, IL-12 p70, IFN-g, and TNF-a) were analyzed
using the Human Pro-inﬂammatory 7-plex Ultra-Sensitive Kit (Meso
Scale Discovery) according to manufacturers instruction. Recovery and
dilution linearity tests were performed on randomly selected SF
samples. Values below lower limit of quantiﬁcation (LLOQ) were
assigned half the LLOQ value for each cytokine. Concentrations were not
normally distributed and thus between group differences were
analyzed using the Mann-Whitney U-test and correlations using
Spearman's rank test (rS).
Results: The serum concentrations of IL-1b, IL-6, IL-12p70 and IFN-g
were below LLOQ for 73-100% of the analyzed samples and were
therefore excluded. IL-10 was detectable in 50% of the samples, while
TNF-a and IL-8 were detectable in all serum samples. Serum concen-
trations of IL-8 were signiﬁcantly lower in the injured group at all time
points, except at 16 weeks, when compared with the reference group
(Table 1).
The SF concentrations of IL-1b and IL-12 p70 were below LLOQ for 59-
100% of the samples and were excluded. Compared to the reference
group, SF concentrations of IL-6, IL-8, IL-10, IFN-g and TNF-a were
signiﬁcantly elevated in the injured group at baseline. IL-6 levels at
baseline were about 1800 times higher compared with the reference
group, thereafter levels decreased, and after 30 weeks and later no
signiﬁcant differences were observed. The SF concentration of TNF-
a was elevated directly after injury and remained signiﬁcantly
elevated over 5 years compared to the reference group (Table 1).
Further, a positive correlation was observed between SF and serum for
IL-8 (rS¼0.156, p¼0.004) and TNF- a (rS¼0.109, p¼0.043)
concentrations.tile range), P-values for group comparisons between references against ACL patients
IL-10 TNF-a
Conc. P-values Conc. P-values
1.0 (1.0-2.4) - 2.2 (1.0-3.6) -
2.2 (1.0-6.5) - 5.9 (4.9-7.3) -
20.1 (8.8-41.1) <0.001 12.4 (9.8-15.2) <0.001
1.0(1.0-3.0) 0.205 6.3 (5.2-7.7) 0.303
2.8 (1.0-4.7) 0.089 5.8 (4.8-7.2) <0.001
2.0 (1.0-2.8) 0.483 6.3 (5.3-7.7) 0.240
1.0 (1.0-2.4) 0,889 4.7 (3.9-6.2) 0.001
1.0 (1.0-3.6) 0.271 6.5 (5.4-7.3) 0.185
1.0 (1.0-2.1) 0.368 4.4 (3.4-5.6) 0.001
1.0 (1.0-2.6) 0.191 6.3 (5.3-6.9) 0.461
1.0 (1.0-2.3) 0.396 4.0 (3.2-4.8) 0.002
1.0 (1.0-2.8) 0.163 6.3 (5.4-7.5) 0.237
1.0 (1.0-1.0) 0.070 3.7 (2.5-4.5) 0.044
2.0 (1.0-3.6) 0.530 6.5 (5.1-8.0) 0.199
IFN-g
P-values Conc. P-values
- 0.6 (0.6-0.6) -
<0.001 8.0 (2.9-28.1) <0.001
0.005 0.6 (0.6-1.4) 0.372
0.209 0.6 (0.6-0.6) 0.387
0.528 0.6 (0.6-0.6) 0.670
0.895 0.6 (0.6-0.6) 0.564
0.588 0.6 (0.6-0.6) 0.446
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S73Conclusions: Pro-inﬂammatory cytokines are elevated in SF, but not in
serum, immediately after knee ACL injury. SF TNF-a level stay elevated
over the ﬁrst 5 years after ACL injury and this high TNF- a concentration
may contribute to a later development of OA.
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MULTIPLEX ANALYSIS OF OSTEOARTHRITIC SYNOVIAL FLUID:
A COMPARISON OF LUMINEX & MESOSCALE DISCOVERY
C. Jayadev, S. Snelling, A. Price, P. Hulley. Univ. of Oxford, Oxford, United
Kingdom
Purpose: Multiplex immunoassay platforms are indispensible for
biomarker discovery. They allow high-throughput, multiple parallel
analysis of precious small volume samples. The 2 dominant technolo-
gies are Luminex (LX) and MesoScale Discovery (MSD). Neither plat-
form is validated for synovial ﬂuid (SF) analysis. The cross-comparison
of multiplex formats and comparison against the existing gold standard
of ELISA are required to facilitate quality control and guide optimum
assay selection for biomarker discovery. Previous comparison studies in
culture medium and serum/plasma cannot be extrapolated to the
complex biological matrix of SF. The aim was to make a detailed
comparison between LX and MSD platforms during the analysis of
real clinical SF samples from end-stage knee OA.
Methods: SF aliquots from patients with end-stage knee OA (N¼31)
were analysed for the inﬂammatory cytokines IL1b, TNFa, IL6 & IL8
using magnetic-bead LX and MSD multiplex assays. All SF samples
underwent identical collection, processing, storage and hyaluronidase
treatment. Aliquots of an additional SF sample were analysed by each
platform after spiking with 2 known concentrations (high & low) of the
respective assay calibrator. ELISA for IL6 & TNFa was performed on
aliquots from patients previously analysed by the LX (n¼8) and MSD
(n¼11) platforms. The LX and MSD assays were compared for limits of
detection (LOD) & quantiﬁcation (LOQ), spike recovery, and intra-assay
precision. Agreement of cytokine measurements between platforms
and against ELISA was tested by: weighted Deming Regressions (WDR),
concordance correlation coefﬁcient (CCC) for absolute agreement and
intraclass correlation coefﬁcient (ICC) for consistency. P<0.05 was
considered signiﬁcant.
Results: LOD: The MSD platform had a signiﬁcantly lower LOD for all 4
analytes (p<0.01). IL6 & IL8 were >LOD in all samples on both plat-
forms. IL1b & TNFa were >LOD in signiﬁcantly more samples on the
MSD platform: IL1b 81% vs 3% (p<0.001); TNF-a 100% vs 3% (p<0.001).
LOQ: The MSD platform had the lowest LOQ for all 4 analytes, which
was signiﬁcant for all except IL6. Both platforms were able to quantify
IL6 & IL8 in >96% of samples. IL1b & TNFa were not quantiﬁable by the
LX assay compared to 29% (p¼0.003) and 87% (p<0.001) by the MSD
assay. Spike-recovery: Spike recoveries on the MSD platform were
acceptable (10020%) for both concentrations except for the IL6 low-
spike (76.6%). IL6 & IL8 had acceptable recoveries for both spikes
concentrations on the LX platform. Recoveries at either spike concen-
trations were below acceptable for IL1b & TNFa. Intra-assay precision:
The coefﬁcient of variation (CV) for replicate measurements for all
analytes was acceptable (<20%) irrespective of platform. There was no
signiﬁcant difference in median CV between platforms. ELISA valida-
tion: All samples were <LOD on the TNFa ELISA. There was no signiﬁ-
cant systematic or proportional error for IL6 measurements by the
either platform vs ELISA (WDR). There was moderate concordance for
MSD vs ELISA (CCC¼0.901) and poor concordance for LX vs. ELISA
(CCC¼0.768) The consistency of measurements for both platforms vs
ELISA was excellent (>0.90). Cross-platform agreement: There wasTable 1
Cross-sectional ARGS-aggrecan concentrations (nM) in synovial ﬂuid (SF) and serum af
percentiles) with fold difference of the medians compared to REF. P-values, Mann-Whitn
n SF-ARGS fold dif. p-values
REF 21 0.85 (0.57, 1.30) - -
Baseline 51 6.85 (4.41,17.25) 8.1 <0.001
16 weeks 50 1.22 (1.00, 1.89) 1.4 0.005
30 weeks 48 1.10 (0.77, 1.77) 1.3 0.068
1 year 49 0.95 (0.74, 1.32) 1.1 0.349
2 years 85 1.07 (0.79, 1.28) 1.3 0.138
5 years 63 1.01 (0.69, 1.39) 1.2 0.266proportional bias but no systematic bias in IL6 & IL8 measurements
between platforms. The concordance of IL6 (CCC¼0.62) and IL8
(CCC¼0.53) measurements was poor, but the relative agreement was
excellent (ICC>0.95).
Conclusions: The MSD platform is better able to detect and quantify
low-level analytes (IL1b & TNFa) in OA SF samples than LX. There is poor
absolute agreement but excellent relative agreement between plat-
forms. This is most likely due to differences in antibody pairs and
kinetics. Cytokine measurements in OA samples are at best semi-
quantitative and depend on the platform, assay and manufacturer, thus
making comparisons between studies difﬁcult. Biomarker studies
should be consistent and explicit regarding assays.
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LONGITUDINAL CHANGE IN SYNOVIAL FLUID AND SERUM LEVELS OF
ARGS-AGGRECAN OVER 5 YEARS AFTER ANTERIOR CRUCIATE
LIGAMENT INJURY
S. Larsson y, M. Hansson y, R. Frobell y, L.S. Lohmander y,z,
A. Struglics y. yDept. of Orthopaedics, Clinical Sci. Lund, Lund Univ.,
Lund, SWEDEN; zRes. Unit for Musculoskeletal Function and
Physiotherapy, and Dept. of Orthopaedics and Traumatology, Univ. of
Southern Denmark, Odense, Denmark
Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the
interglobular domain of aggrecan, releasing N-terminal 374ARGS frag-
ments into synovial ﬂuid (SF-ARGS), is an early key event in arthritis
and joint injuries. We have previously shown that SF-ARGS is associated
with radiographic progression of knee osteoarthritis (OA) as well as
with progression of self-reported pain after meniscectomy. As a part of
a randomized controlled study (KANON), initiated to investigate
structured rehabilitation of anterior cruciate ligament (ACL) injuries
with or without surgical reconstruction, we here report ARGS-aggrecan
levels in SF and in serum over 5 years after ACL injury.
Methods: One hundred and twenty-one subjects (26% women, mean
age 26 years, standard deviation [SD] 4.9 years) with an ACL rupture to
a previously un-injured knee were followed within 3 weeks from
trauma (baseline), at 16 weeks, 30 weeks, 1 year, 2 years and 5 years.
Blood samples were obtained from all subjects and SF was collected
from a subset of subjects (6 subjects had intact series of both SF and
serum samples). Twenty-one knee-healthy individuals (38% women,
mean age 28 years, SD 9.4 years) were used as reference. Levels of
ARGS-aggrecan were measured in all SF and serum samples with an
electrochemiluminescence immunoassay using an anti-aggrecan anti-
body (AHP0022; Invitrogen) for capture, and a monoclonal anti-ARGS
(OA-1) for detection. We used Mann-Whitney rank sum test for
comparison of ARGS-concentrations at different time points compared
to knee-healthy references, and Spearman's rank order correlation for
assessment of correlation, based on Shapiro-Wilk test indicating
skewed distributions at all time points.
Results: Levels of ARGS-aggrecan in SF and serum correlated (Spear-
man's rho¼ 0.245, p< 0.001, n¼ 356) and were overall 10 times higher
in SF than in serum: median nM ARGS in SF (25th and 75th percentiles)
in ACL injured at all time points combined 1.16 (0.83, 1.94) and 0.13
(0.10, 0.17) in serum.
SF-ARGS levels in the ACL injury group were elevated compared to
knee-healthy references at baseline and at 16 weeks after injury, but
after 30 weeks or longer, levels were not signiﬁcantly different from
those observed in the reference group (Table 1). ACL injury serum-ARGS
levels compared to knee-healthy reference level were signiﬁcantly
elevated at baseline but not at any other time point (Table 1).ter ACL injury and in knee-healthy subjects (REF). Values are medians (25th, 75th
ey rank sum tests against uninjured references.
n serum-ARGS fold dif. p-values
19 0.112 (0.075, 0.138) - -
120 0.158 (0.114, 0.198) 1.4 0.002
64 0.134 (0.099, 0.168) 1.2 0.073
63 0.137 (0.107, 0.164) 1.2 0.075
63 0.129 (0.105, 0.157) 1.2 0.148
118 0.125 (0.094, 0.153) 1.1 0.290
115 0.113 (0.091, 0.143) 1.0 0.784
